Use of recombinant tissue-plasminogen activator in a dog with chylothorax secondary to catheter-associated thrombosis of the cranial vena cava

Journal of the American Animal Hospital Association

Volumn 38, Issue 5, 2002, Pages 431-435

  Bliss, Stuart P ^a   Bliss, Susan K ^a   Harvey, H Jay ^a  

^a Animal Health Diagnostic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTITHROMBIN III; ENROFLOXACIN; FRESH FROZEN PLASMA; HEPARIN; HETASTARCH; IODINATED CONTRAST MEDIUM; OXYMORPHONE; RINGER LACTATE SOLUTION; SERUM ALBUMIN;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CENTRAL VENOUS CATHETERIZATION; CHYLOTHORAX; DOG; ESOPHAGOSTOMY; FIBRINOLYTIC THERAPY; JUGULAR VEIN; MALE; NONHUMAN; POSTOPERATIVE INFECTION; SEPSIS; SUPERIOR CAVA VEIN; TUBE; VEIN THROMBOSIS;

CANIS FAMILIARIS;

EID: 0036713420     PISSN: 05872871     EISSN: None     Source Type: Journal    
DOI: 10.5326/0380431     Document Type: Article

References (31)

1. Combined chylothorax, chylopericardium, and cranial vena cava syndrome in a dog with thymoma
2. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996)
3. Intravenous catheter placement for fluid therapy and for central venous pressure measurements in small animals
4. Blastomycosis granuloma involving the cranial vena cava associated with chylothorax and cranial vena caval syndrome in a dog
5. Chylothorax in the dog and cat: A review
6. Lymphangiographic evaluation of experimentally induced chylothorax after ligation of the cranial vena cava in dogs
7. Lymphangiography and ligation of the canine thoracic duct: A study in normal dogs and three dogs with chylothorax
8. The sepsis-coagulant axis: A review
9. Central venous catheter related thrombosis
10. Thrombolytic therapy: Current status
11. Thrombolytic therapy in dogs and cats
12. Use of streptokinase in four dogs with thrombosis
13. Use of recombinant tissue-plasminogen activator for aortic thrombolysis in a hypoproteinemic dog
14. Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs
15. Comparative safety of thrombolytic agents
16. The pharmacology of aspirin, heparin, coumarin, and thrombolytic agents
17. Thrombolytic therapy for deep venous thrombosis: A clinical review
18. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator
19. Reperfusion adjunctive therapy
20. New developments in thrombolytic therapy
21. Heparin inhibits spontaneous thrombolysis. and the thrombolytic effect of both streptokinase and tissue-type plasminogen activator. An in vitro study of the dislodgement of platelet-rich thrombi formed from native blood
22. Platelets and thrombolytic therapy
23. Antithrombotic and fibrinolytic factors, a review
24. Studies on the release of a plasminogen activator inhibitor by human platelets
25. Complex formation of platelet thrombospondin with plasminogen: Modulation of activation by tissue activator
26. Tissue-type plasminogen activator and streptokinase induced platelet hyperaggregability in the rabbit
27. Platelets and fibrinolysis
28. The platelet fibrinogen receptor
29. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity
30. Plasmin effect on platelet glycoprotein Ib-vonWillebrand factor interactions
31. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-22